ACS Medicinal Chemistry Letters

Enantioselective Synthesis and Profiling of Two Novel Diazabicyclooctanone β -Lactamase Inhibitors

Hui Xiong, Brendan Chen, Thomas F. Durand-Réville,* Camil Joubran, Yun W. Alelyunas, Dedong Wu, and Hoan Huynh

Infection Innovative Medicines, AstraZeneca Pharmaceuticals, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

(5) Supporting Information



ABSTRACT: The enantioselective synthesis of two novel cyclopropane-fused diazabicyclooctanones is reported here. Starting from butadiene monoxide, the key enone intermediate 7 was prepared in six steps. Subsequent stereoselective introduction of the cyclopropane group and further transformation led to compounds 1a and 1b as their corresponding sodium salt. The great disparity regarding their hydrolytic stability was rationalized by the steric interaction between the cyclopropyl methylene and urea carbonyl. These two novel β -lactamase inhibitors were active against class A, C, and D enzymes.

KEYWORDS: β -lactamase inhibitor, asymmetric synthesis, hydrolytic stability

S ince the discovery of penicillin in the 1920s, β -lactam antibiotics have become one of the most important groups of antibiotics. The worldwide usage of these antibiotics has rapidly led to the development of bacterial resistance, mainly by the production and evolution of β -lactamases, which are enzymes responsible for efficiently catalyzing the hydrolysis of the β -lactam warheads. According to the Ambler classification,¹⁻³ β -lactamases are divided into four subfamilies: class A, C, and D enzymes have a key serine residue in the active site, whereas class B enzymes (also called metallo- β -lactamases) employ either one or two zinc ions.

The combination use of several mechanism-based β lactamase inhibitors (clavulanic acid, sulbactam, and tazobactam) with β -lactam antibiotics is currently one of the most successful strategies in combating such resistance,⁴⁻⁶ as evident by the wide clinical application of products such as Augmentin, Timentin, Unasyn, Sulperazone, and Zosyn. However, these β lactamase inhibitors only have activity against class A β lactamases and weak or no activity against class C and D enzymes.⁴ In addition, β -lactamases are rapidly evolving, as evident by the rising number of new β -lactamases reported each year (over 1400 to date).⁷ Therefore, this urgent medical need calls for firm commitment to the discovery and development of novel and more efficient inhibitors with broader coverage of β lactamases.

Recently a novel series of β -lactamase inhibitors based on the diazabicyclooctanone (DBO) scaffold was reported.^{8–10} Avibactam (NXL104)^{11–13} and MK-7655,^{14–16} with their common bicyclic urea structure (Figure 1), were reported to have limited intrinsic antibiotic activity, but are capable of

inhibiting classes A and C and a limited number of class D β -lactamases.



Figure 1. Chemical structures of selected examples of diazabicyclooctanones (DBO).

This letter describes our efforts toward the enantioselective synthesis of two new cyclopropane-fused diazabicyclooctanones **1a** and **1b** aiming to explore whether the introduction of additional ring strain can lead to higher reactivity of the urea carbonyl and broader β -lactamase coverage, while hoping to maintain sufficient hydrolytic stability.

Received: July 10, 2014 Accepted: August 12, 2014 As shown in Scheme 1, the synthesis started with the Pdcatalyzed dynamic kinetic asymmetric transformation





(DYKAT) of racemic butadiene monoxide 2 employing phthalimide, $Pd(allyl)_2Cl_2$, and the (R,R)-DACH-naphthyl ligand.¹⁷ This reaction was highly reproducible and scalable, and alcohol 3 was consistently obtained in >90% yield and >95% ee on >100 g scale. Subsequent TBS protection and treatment with hydrazine in methanol gave amine 4 in high yield. Over reduction of the alkene by hydrazine was sometimes observed but could be controlled by limiting the reaction time. Monoalkylation of the primary amine, followed by Boc protection, afforded the Weinreb amide 5 in 66% yield. It is noteworthy that numerous attempts (various bases, solvents, additives, and temperatures) to alkylate the Boc carbamate of amine 4 led to low conversion. The addition of propenylmagnesium bromide to Weinreb amide 5 gave vinyl ketone 6, which was then treated with 2 mol % of the second generation Hoveyda-Grubbs catalyst¹⁸ in hot toluene to form the enone ring in good yield. The use of propenylmagnesium bromide led to higher yields in both the vinyl ketone formation and metathesis steps relative to vinylmagnesium bromide.

With enone intermediate 7 in hand, we next explored the introduction of the cis-cyclopropane ring (Scheme 2). Stereoselective Luche reduction¹⁹ of the enone gave allylic alcohol 8 as a single diastereomer in 65% yield. The stereochemical outcome of this transformation was confirmed by an observed nuclear Overhauser effect (NOE) from the TBS ether methylene group to the axial proton H_{6a} (Figure 2). In addition, proton H_{6a} was determined to be axial due to its large trans diaxial coupling constant with proton H_{5a} (10.5 Hz). Hydroxyl-directed cyclopropanation of allylic alcohol 8 under Denmark's modified conditions²⁰ afforded compound 9 as a single diastereomer in 77% yield. The cyclopropanation of the double bond occurred on the same face of the alcohol group as confirmed by the presence of NOEs observed in compound 9 (Figure 2). Alcohol 9 was then converted to compound 10 under Mitsunobu conditions using dinitrobenzenesulfonyl protected O-benzylhydroxylamine.

Selective deprotection of the Boc group in the presence of the TBS ether was achieved employing either TBSOTf^{21} or $\text{ZnBr}_2^{22,23}$ in comparable yields. Subsequent removal of the nitrobenzenesulfonyl group gave free diamine 11 in 50% yield over 2 steps.

Scheme 2. Synthesis of Compound 1a



Figure 2. Assignment of relative stereochemistry by nuclear magnetic resonance (NMR). Each double arrow indicates a signal observed in the NOE experiments.

The bicyclic urea ring was formed via slow addition of a triphosgene solution to a dilute solution of diamine and Hünig's base in CH₃CN at 0 °C. The TBS ether was removed with TBAF. The resulting alcohol 13 (relative stereochemistry confirmed by X-ray analysis, see Supporting Information) was oxidized to the corresponding carboxylic acid 14 under mild conditions using catalytic $\text{CrO}_{3^{\prime}}^{24}$ which was then converted to primary amide 15. NOE experiments confirmed the stereochemistry at C2 remained intact through the oxidation and amide coupling steps (Figure 2). This could be explained by the rigid nature of the DBO scaffold where the highly strained system prevents the formation of the required tautomer to allow the epimerization to occur. Next the benzyl group was removed under catalytic hydrogenolysis conditions. After filtration and concentration, the N-hydroxide intermediate was treated with excess SO3-pyridine complex in pyridine to drive the sulfate formation. Finally target compound 1a was isolated as its sodium salt after treatment with NaOH preconditioned Dowex ion-exchange resin.

Next we turned our attention to the preparation of the other cyclopropane diastereomer **1b**. We reasoned that this could be accomplished by carrying out the cyclopropanation before formation of the alcohol, thus relying on steric hindrance to direct the stereochemical outcome of the reaction. As shown in Scheme 3, slow addition of enone 7 to a dilute solution (\sim 0.05

Scheme 3. Synthesis of Urea 19



M) of preformed sulfoxonium vlide 25,26 in THF resulted in the formation of the cyclopropane 16 in good yield. The trans stereochemistry was established by NOE experiments (Figure 2). We hypothesized that the reduction of an oxime derived from ketone 16 would stereoselectively provide the desired trans-isomer due to the steric hindrance of the cyclopropane ring. To this end, ketone 16 was readily converted to the Obenzyl oxime, which was subsequently reduced to hydroxylamine 17 using a large excess of NaBH₃CN and boron trifluoride-diethyl etherate, albeit in moderate vield. Selective removal of the Boc group, followed by urea formation, led to the formation of the bicyclic urea 19. The relative stereochemistry of the rigid bicyclic urea 19 was readily determined by NOE experiments to be the undesired *cis* isomer (Figure 2). It is therefore clear that the presence or absence of the cyclopropane did not play a role in the stereoselectivity of the ketone reduction. As in the stereoselective reduction of enone 7 (Scheme 2), the large TBS ether group in its pseudoaxial position directed the axial attack of the hydride on the carbonyl/oxime group.

Alternatively, cyclopropanone 16 was reduced with a sterically undemanding NaBH₄ at 0 °C to provide the cis alcohol 20 in excellent yield and greater than 10 to 1 diastereoselectivity (Scheme 4). Following the previously established synthetic sequence used for the preparation of compound 1a, alcohol 20 was converted to primary amide 25. Catalytic hydrogenolysis of 25 to remove the benzyl protective group, sulfate formation, ion exchange, and RP-HPLC purification furnished the final compound 1b as its sodium salt in 45% yield over the final 3 steps. As shown in Figure 3, confirmation of the structure of 1b was obtained via a small molecule crystal structure.

With diastereomeric cyclopropane analogues 1a and 1b in hand, we examined their hydrolytic stability in pH 7.4 (aqueous phosphate buffer). Compound 1a was stable with a half-life of 112 h at 37 °C. As expected, at elevated temperature (70 °C), the half-life of 1a was significantly shorter (8.2 h). Compound 1b was remarkably more stable, as evident by its long half-life (>264 h) even at 70 °C in pH 7.4 aqueous phosphate buffer. As





Figure 3. X-ray crystal structure of 1b.

a reference, the half-life of the known β -lactamase inhibitor tazobactam in the same conditions was measured at 7.7 h, a value very similar to that of compound **1a**.

The exceptional stability of **1b** may be rationalized by its concave conformation (Figure 3). The rigid tricyclic structure and particular stereochemistry places the cyclopropane methylene group of **1b** in close proximity (C2–C7 distance = 2.48 Å) to the carbonyl group of the cyclic urea. This may provide a strong steric protection from the addition of water and also destabilize the tetrahedral intermediate that would be formed during hydrolysis.

Furthermore, the two novel cyclopropane-containing DBOs **1a** and **1b**, together with tazobactam were profiled for their inhibitory activities against a series of β -lactamases. As presented in Table 1, both analogues showed activity against class A, C, and D β -lactamases. This suggests that the measurement of hydrolytic stability is not enough to predict reactivity with β -lactamases. Additional factors like molecular recognition and acylation rates come into play in the stepwise mechanism of covalent inhibition.^{27,28} While the levels of inhibition were variable across the 3 families of β -lactamases, the structure–activity relationship (SAR) between the two new analogues and tazobactam represents useful information to

Table 1. Enzyme Inhibition against Different Classes of β -Lactamases

	class A IC ₅₀ (µM)		class C IC ₅₀ (µM)	class D IC ₅₀ (µM)
compound	CTX-M-15 K. pneumoniae	KPC-2 E. cloacae	AmpC P. aeruginosa	OXA-48 K. pneumoniae
Tazobactam	< 0.007	39	3.4	3.6
1a	0.14	0.85	4.5	1.3
1b	0.48	6.7	2.0	28

design the next generation of DBO-based β -lactamase inhibitors. The increased hydrolytic stability for those new inhibitors will also represent an advantage in terms of formulation development and manufacturing.

In summary, the enantioselective synthesis of two novel tricyclic DBO analogues was accomplished in 17 linear steps (1.8% and 0.6% overall yield, respectively). Compound **1b** has demonstrated excellent aqueous stability at physiological pH, demonstrating the fundamental differences between ring strain and stability. Additionally, the biochemical data presented herein further illustrates the lack of direct correlation between reactivity and enzymatic activity for covalent inhibitors. Additional SAR exploration will be required to better understand the stability and improve the enzymatic activity of this exciting new class of β -lactamase inhibitors.

ASSOCIATED CONTENT

S Supporting Information

Representative assay protocols, experimental procedures, and spectroscopic data for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

■ AUTHOR INFORMATION

Corresponding Author

*(T.F.D.-R.) Tel: 781-472-5943. Fax: 781-472-5925. E-mail: thomas.durandreville@astrazeneca.com.

Notes

The authors declare the following competing financial interest(s): The authors are all current or former employees of AstraZeneca and may possess AstraZeneca stock.

ACKNOWLEDGMENTS

We thank Nancy DeGrace for assistance with the NMR experiments, Lise Gauthier for the RP-HPLC purification, Ying Liu for the HRMS studies, and Tiffany Palmer for generating the β -lactamase inhibition data.

REFERENCES

(1) Ambler, R. P. The structure of β -lactamases. *Philos. Trans. R. Soc. London, Ser. B* **1980**, 289, 321–331.

(2) Hall, B. G.; Barlow, M. J. Revised Ambler classification of β -lactamases. Antimicrob. Chemother. **2005**, 55, 1050.

(3) Bush, K.; Jacoby, G. A. Updated functional classification of β -lactamases. Antimicrob. Agents Chemother. **2010**, 54, 969.

(4) Drawz, S. M.; Bonomo, R. A. Three decades of β -lactamase inhibitors. *Clin. Microbiol. Rev.* **2010**, *23*, 160 and references therein..

(5) Bebrone, A.; Lassaux, P.; Vercheval, L.; Sohier, J.-S.; Jehaes, A.; Sauvage, E.; Galleni, M. Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition. *Drugs* **2010**, *70*, 651.

(6) Bush, K.; Macielag, M. J. New β -lactam antibiotics and β -lactamase inhibitors. *Expert Opin. Ther. Pat.* **2010**, 20, 1277.

(7) http://www.lahey.org/studies/.

(8) Stachyra, T.; Pechereau, M. C.; Bruneau, J. M.; Claudon, M.; Frère, J. M.; Miossec, C.; Coleman, K.; Black, M. T. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non- β -lactam β -lactamase inhibitor. *Antimicrob. Agents Chemother.* **2010**, 54, 5132.

(9) Livermore, D. M.; Mushtaq, S.; Warner, M.; Zhang, J.; Maharjan, S.; Doumith, M.; Woodford, N. Activity of NXL104 in combination with β -lactams against genetically characterized *Escherichia coli* and *Klebsiella pneumoniae* isolates producing class A extended-spectrum β -lactamases and class C β -lactamases. *Antimicrob. Agents Chemother.* **2011**, 55, 390.

(10) Coleman, K. Diazabicyclooctanes (DBOs): a potent new class of non- β -lactam β -lactamase inhibitors. *Curr. Opin. Microbiol.* **2011**, *14*, 550 and references therein..

(11) Bonnefoy, A.; Dupuis-Hamelin, C.; Steier, V.; Delachaume, C.; Seys, C.; Stachyra, T.; Fairley, M.; Guitton, M.; Lampilas, M. *In vitro* activity of AVE1330A, an innovative broad-spectrum non- β -lactam β lactamase inhibitor. *J. Antimicrob. Chemother.* **2004**, *54*, 410.

(12) Boyd, J. A.; Cherryman, J. H.; Golden, M.; Kalyan, Y. B.; Lawton, G. R.; Milne, D.; Phillips, A. J.; Racha, S.; Ronsheim, M. S.; Telford, A. Process for preparing heterocyclic compounds including *trans*-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof. Patent WO2012172368, 2012.

(13) Ehmann, D. E.; Jahic, H.; Ross, P. L.; Gu, R. F.; Hu, J.; Kern, G.; Walkup, G. K.; Fisher, S. L. Avibactam is a covalent, reversible, non- β -lactam β -lactamase inhibitor. *Proc. Natl. Acad. Sci. U.S.A.* **2012**, *109*, 11663.

(14) Mangion, I. K.; Ruck, R. T.; Rivera, N.; Huffman, M. A.; Shevlin, M. A concise synthesis of a β -lactamase inhibitor. *Org. Lett.* **2011**, *13*, 5480.

(15) Miller, S. P.; Zhong, Y.-L.; Liu, Z.; Simeone, M.; Yasuda, N.; Limanto, J.; Chen, Z.; Lynch, J.; Capodanno, V. Practical and costeffective manufacturing route for the synthesis of a β -lactamase inhibitor. *Org. Lett.* **2014**, *16*, 174.

(16) Blizzard, T. A.; Chen, H.; Kim, S.; Wu, J.; Bodner, R.; Gude, C.; Imbriglio, J.; Young, K.; Park, Y.-W.; Ogawa, A.; Raghoobar, S.; Hairston, N.; Painter, R. E.; Wisniewski, D.; Fitzgerald, P.; Sharma, N.; Lu, J.; Ha, S.; Hermes, J.; Hammond, M. L. Discovery of MK-7655, a β -lactamase inhibitor for combination with Primaxin. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 780.

(17) Trost, B. M.; Horne, D. B.; Woltering, M. J. Palladium-catalyzed DYKAT of vinyl epoxides: enantioselective total synthesis and assignment of the configuration of (+)-Broussonetine G. Angew. Chem., Int. Ed. 2003, 42, 5987.

(18) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. Efficient and recyclable monomeric and dendritic Ru-based metathesis catalysts. *J. Am. Chem. Soc.* **2000**, *122*, 8168.

(19) Gemal, A. L.; Luche, J. L. Lanthanoids in organic synthesis. 6. Reduction of alpha-enones by sodium borohydride in the presence of lanthanoid chlorides: synthetic and mechanistic aspects. *J. Am. Chem. Soc.* **1981**, *103*, 5454.

(20) Denmark, S. E.; Edwards, J. P. A comparison of (chloromethyl)and (iodomethyl)zinc cyclopropanation reagents. *J. Org. Chem.* **1991**, 56, 6974.

(21) Grieco, P. A.; Hon, Y. S.; Perez-Medrano, A. Convergent, enantiospecific total synthesis of the novel cyclodepsipeptide (+)-jasplakinolide (jaspamide). *J. Am. Chem. Soc.* **1988**, *110*, 1630.

(22) Nigam, S. C.; Mann, A.; Taddei, M.; Wermuth, C.-G. Selective removal of the *tert*-butoxycarbonyl group from secondary amines: ZnBr2 as the deprotecting reagent. *Synth. Commun.* **1989**, *19*, 3139.

(23) Murray, A. J.; Parsons, P. J.; Hitchcock, P. The combined use of stereoelectronic control and ring closing metathesis for the synthesis of (-)-8-*epi*-swainsonine. *Tetrahedron* **2007**, *63*, 6485.

(24) Zhao, M.; Li, J.; Song, Z.; Desmond, R.; Tschaen, D. M.; Grabowski, E. J. J.; Reider, P. J. A novel chromium trioxide catalyzed oxidation of primary alcohols to the carboxylic acids. *Tetrahedron Lett.* **1998**, *39*, 5323.

(25) Corey, E. J.; Chakovsky, M. Dimethyloxosulfonium methylide $((CH_3)_2SOCH_2)$ and dimethylsulfonium methylide $((CH_3)_2SCH_2)$.

Formation and application to organic synthesis. J. Am. Chem. Soc. 1965, 87, 1353.

(26) Gololobov, Y. G.; Nesmeyanov, A. N.; lysenko, V. P.; Boldeskul, I. E. Twenty-five years of dimethylsulfoxonium ethylide (Corey's reagent). *Tetrahedron* **1987**, *43*, 2609.

(27) Sykes, N. O.; Macdonald, S. J. F.; Page, M. I. Acylating agents as enzyme inhibitors and understanding their reactivity for drug design. *J. Med. Chem.* **2002**, *45*, 2850.

(28) Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs. *Nat. Rev. Drug Discovery* **2011**, *10*, 307.